Cefpodoxime Proxetil — A Prodrug Designed for Oral Bioavailability
The "proxetil" in cefpodoxime proxetil isn't cosmetic — it's the entire reason this third-generation cephalosporin can be taken as a tablet at all. Cefpodoxime in its active acid form has poor oral absorption. Esterifying it to the proxetil prodrug form dramatically improves lipophilicity and intestinal permeability. After absorption, non-specific esterases in the intestinal mucosa and plasma hydrolyse the ester bond, releasing active cefpodoxime into systemic circulation.
Active cefpodoxime then binds penicillin-binding proteins (PBP), disrupting peptidoglycan cross-linking and causing bacterial cell lysis — with a third-generation spectrum that includes Haemophilus influenzae, Moraxella catarrhalis, E. coli, Klebsiella, and Proteus, alongside retained gram-positive activity against Streptococcus pneumoniae and Streptococcus pyogenes.
Potassium Clavulanate 125mg irreversibly inhibits bacterial beta-lactamase enzymes — protecting cefpodoxime from hydrolysis by resistant strains and restoring efficacy against organisms that would otherwise inactivate the cephalosporin before it reaches its PBP target. This combination is particularly valuable against beta-lactamase-producing H. influenzae and M. catarrhalis — common in resistant respiratory and ENT infections.
For pharma brands sourcing a cefpodoxime clavulanate manufacturer, this prodrug-plus-inhibitor combination represents a clinically differentiated, broader-spectrum alternative to standard amoxycillin-clavulanate products.
Clinical Uses of Cefpodoxime and Potassium Clavulanate Tablets
Respiratory Tract Infections — Cefpodoxime's gram-negative coverage makes it effective in community-acquired pneumonia and acute bronchitis, particularly where H. influenzae resistance is suspected.
Sinusitis, Tonsillitis & Otitis Media — The combination targets the predominant ENT pathogens — S. pneumoniae, H. influenzae, M. catarrhalis — including beta-lactamase-producing strains responsible for treatment failure on plain antibiotics.
Urinary Tract Infections — Third-generation cephalosporin coverage against E. coli, Klebsiella, and Proteus makes this a reliable option for uncomplicated and recurrent UTIs, especially in patients with prior antibiotic exposure.
Skin & Soft Tissue Infections — Effective against Staphylococcus aureus and Streptococcus pyogenes, including beta-lactamase-producing strains seen in recurrent cellulitis and wound infections.
Pharyngitis & Tonsillitis — A reliable alternative where penicillin-class resistance or treatment failure has occurred.
For pharma brands, this breadth means a single SKU addresses respiratory, ENT, urological, and dermatological prescribing — a genuinely multi-segment product.
Formulation Stability — Manufacturing Cefpodoxime Proxetil Clavulanate Tablets
Cefpodoxime proxetil is moisture-sensitive and exists in multiple polymorphic forms with different dissolution profiles — meaning the granulation method directly affects bioavailability and batch-to-batch consistency. Clavulanate, similarly, is hygroscopic and degrades rapidly in the presence of moisture and heat.
Delwis Healthcare's tablet manufacturing addresses both challenges:
- Controlled wet granulation with low-moisture processing to prevent clavulanate degradation during blending
- Polymorphic form control for cefpodoxime proxetil, ensuring consistent dissolution batch-to-batch
- Film coating providing a moisture barrier that protects both APIs through shelf life
- In-process dissolution and moisture monitoring at each production stage
- 10×6 Alu-Alu blister packaging — full moisture and light barrier critical for this hygroscopic combination
This level of formulation control is what separates a reliable cephalosporin clavulanate tablet manufacturer from a generic toll producer — particularly for a combination where both APIs carry real stability risk.
Manufacturing Partnership Options — Cefpodoxime Clavulanate Tablets
Delwis Healthcare is a WHO-GMP certified third party manufacturer and CDMO partner for cefpodoxime and potassium clavulanate tablets, offering:
- Third Party Manufacturing — Full production under your brand, with film-coated tablets, Alu-Alu packing, and labeling — zero infrastructure investment.
- Contract Manufacturing (CDMO) — Formulation stability work, polymorphic form validation, scale-up, stability studies, and regulatory documentation for export and domestic dossiers.
- Private Label Manufacturing — Custom blister branding, carton design, and batch coding for domestic and export markets.
- Bulk Supply — High-volume production for institutional buyers, hospital tenders, and export distributors with full COA and batch documentation.
Pharma companies seeking a cefpodoxime potassium clavulanate tablet contract manufacturer in India or a WHO-GMP antibiotic tablet manufacturer in Gujarat will find our facility technically equipped and compliance-ready.
Quality Control — Testing Protocol for Cefpodoxime Clavulanate Tablets
Every batch undergoes:
- HPLC quantification of both cefpodoxime and clavulanate content per pharmacopoeial standards
- Dissolution profile testing validated against IP/USP specifications
- Moisture content (Karl Fischer) testing — critical given clavulanate's hygroscopic nature
- Content uniformity testing across each batch
- Microbial limit testing for compliance
- ICH-compliant stability studies (real-time and accelerated) for DCGI and export dossiers
- Raw material release testing for both APIs before production begins
Why Pharma Brands Choose Delwis Healthcare for This Combination
- Polymorphic-form expertise for cefpodoxime proxetil — a manufacturing detail most toll producers overlook, directly affecting dissolution consistency
- Moisture-controlled processing purpose-built for clavulanate-containing formulations
- WHO-GMP, ISO 9001, ISO 14001 certified facility in Ahmedabad, Gujarat
- Flexible MOQ — from development batches to commercial volumes
- Full regulatory documentation — stability data, COA, batch records for DCGI and export filings
- Private label and export-ready packaging support across markets
FAQs — Cefpodoxime & Potassium Clavulanate Tablets
Q1: What is cefpodoxime and potassium clavulanate tablet used for?Bacterial infections of the respiratory tract, ENT (sinusitis, tonsillitis, otitis media), urinary tract, and skin — particularly where beta-lactamase-producing pathogens cause resistance to standard antibiotics.
Q2: How is cefpodoxime different from cefpodoxime clavulanate?Plain cefpodoxime is defeated by beta-lactamase-producing bacteria. Clavulanate inactivates this enzyme, restoring cefpodoxime's effectiveness against resistant strains.
Q3: Why "proxetil" rather than just cefpodoxime?Proxetil is the ester prodrug form required for oral absorption — esterases convert it to active cefpodoxime after absorption.
Q4: Should this tablet be taken with food?Yes — improves absorption and reduces GI discomfort, a common cephalosporin side effect.
Q5: What is the shelf life and storage requirement?24 months, stored below 30°C in a dry place, protected from moisture — critical given clavulanate's hygroscopic nature.
Q6: Do you offer third party manufacturing for this combination?Yes — complete contract manufacturing including formulation, Alu-Alu packaging, private labeling, and regulatory documentation. Contact info@delwishealthcare.com.
Q7: What certifications does your facility hold?WHO-GMP, ISO 9001, ISO 14001 — compliant with USP, BP, and IP standards, with full stability and batch documentation.
